AtlasXomics
AtlasXomics is a New Haven-based biotechnology company commercializing its proprietary DBiT-seq microfluidic spatial epigenomics platform. It sells spatial epigenomics services and FlowGel reagent kits to academic and life sciences industry customers, enabling high-resolution chromatin mapping on tissue for oncology, neurology, and aging research.
- Company typePrivate
- Founded2020
- HeadquartersNew Haven, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What AtlasXomics does
AtlasXomics Inc. is a New Haven, Connecticut-based biotechnology company founded in 2020 that develops and commercializes spatial epigenomics technology for tissue-level multi-omic analysis. The company's core offering is the proprietary DBiT-seq platform, which uses two orthogonal microfluidic chips to deliver spatial barcodes across tissue sections, generating pixel-level maps of open chromatin and chromatin marks without requiring tissue dissociation. The platform achieves 48,400 pixels at 10×10 µm resolution per chip on standard laboratory slides, requiring no custom instrumentation, and is supported by an in-house bioinformatics capability.
The company operates a horizontal business model serving two primary customer segments: academic research institutions conducting spatial epigenomics studies and life sciences industry customers (pharmaceutical and biotechnology companies) applying the technology to drug discovery, tissue analysis, and biomarker development. AtlasXomics generates revenue through two streams — fee-for-service spatial epigenomics analysis and the sale of FlowGel reagent kits distributed through an early-access program — with pricing conducted on a quote-based, undisclosed basis. Its commercial motion is sales-led and direct, with the company actively soliciting partnership opportunities to adapt the DBiT-seq platform to new applications and providing grant-support letters to academic customers.
AtlasXomics is anchored scientifically by founder Rong Fan, a Professor of Biomedical Engineering at Yale University, and operates with a leadership team that draws heavily from IsoPlexis alumni and Yale-trained PhD scientists. The advisory board includes senior scientists from UC Berkeley, the Institute for Systems Biology, Princeton, and the Lawrence J. Ellison Institute, while the board of directors brings institutional capital representation through Gregory P. Ho (Chairman, SMC) and John L. Steffens (Founder and Senior Managing Director of Spring Mountain Capital; former Vice Chairman of Merrill Lynch). The company has disclosed approximately $5.69M in cumulative funding across 2021 and 2022, employs 11–50 people, and has not disclosed patents, named customer accounts, or revenue figures.
AtlasXomics firmographics
Firmographics- Name
- AtlasXomics
- Legal name
- AtlasXomics Inc.
- Website
- https://atlasxomics.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- AtlasXomics is a New Haven-based biotechnology company commercializing its proprietary DBiT-seq microfluidic spatial epigenomics platform. It sells spatial epigenomics services and FlowGel reagent kits to academic and life sciences industry customers, enabling high-resolution chromatin mapping on tissue for oncology, neurology, and aging research.
- Ownership category
- akta.pro rank
AtlasXomics industry classification
Industry- Product category
- Spatial Epigenomics Services and Tools
- NAICS
- Medical Laboratories (621511), Analytical Laboratory Instrument Manufacturing (334516)
- SIC
- Services-Medical Laboratories (8071), Laboratory Analytical Instruments (3826)
- akta.pro primary industry
- Epigenomics & Chromatin Profiling Services (HLAGANAF)
- akta.pro secondary industries
- Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI), Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays) (HLAGAIAF)
Keywords
Where AtlasXomics is headquartered
LocationHeadquarters
- HQ city
- New Haven
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
AtlasXomics business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain
Revenue model
- Spatial Epigenomics Services: The company provides spatial epigenomics services to academia and industry, offering multi-omic mapping of tissues as a service offering.
- Early-Access Kits: Sale of FlowGel kits for spatial epigenomics research, available through early-access program.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
AtlasXomics product offering
Product offeringCore offering
AtlasXomics commercializes the proprietary DBiT-seq platform for spatial epigenomics, using orthogonal microfluidic barcoding to map open chromatin and chromatin marks directly on intact tissue sections at high resolution (48,400 pixels at 10×10 µm) without tissue dissociation. The company delivers this capability through three offerings: the DBiT-seq technology platform itself, FlowGel reagent kits for in-situ labeling and library preparation, and contract spatial epigenomics services that produce multi-omic tissue maps for academic and industry clients.
Product overview
AtlasXomics offers a unified platform for spatial epigenomics centered on the DBiT-seq Platform, which combines in situ chemistry, microfluidic spatial barcoding chips, and lysis/library prep workflows to generate high-resolution pixel-level maps of open chromatin and chromatin marks on tissue. The portfolio includes FlowGel reagent kits (add-on modules for the DBiT-seq workflow) and a service offering for clients seeking outsourced spatial epigenomics analysis. The three components are designed to work together as an end-to-end solution for researchers mapping epigenetic regulatory programs on tissue sections.
Differentiator
Problem solved
Functional benefit
Products and services
- DBiT-seq Platform A microfluidic-based spatial epigenomics platform that maps open chromatin and chromatin marks directly on tissue sections using orthogonal A×B spatial barcoding, generating pixel-level maps after sequencing for academic and industry researchers.
- FlowGel Kits Reagent kits for the DBiT-seq workflow that enable in-situ labeling, spatial barcoding, and library preparation for spatial epigenomics applications; sold to academic and industry customers through an early-access program.
- Spatial Epigenomics Service A contract research service that produces multi-omic spatial epigenomics maps of tissues for academic and industry clients, with options for early-access kit programs and partnership-driven adaptation to new applications.
Companies that use AtlasXomics
Customer profileSegments2 records
Ideal customer profiles2 records
AtlasXomics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
AtlasXomics partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Academic Research InstitutionscoreAtlasXomics actively partners with academic institutions to create multi-omic maps of tissues. The company was founded based on technology from Yale University (Rong Fan, Professor of BME), and maintains ongoing collaborations with academic researchers.
- Life Sciences CompaniescoreThe company works with industry partners to adapt their spatial epigenomics technology to various applications. They offer partnership opportunities for companies interested in applying the DBiT-seq platform to new use cases.
Scale indicators2 records
Expansion highlights5 records
AtlasXomics competitors and assessment
Company assessmentDirect peers
- 10x Genomics: Leading spatial omics platform with Visium and Xenium products for spatial transcriptomics and emerging multi-omics. Directly comparable as it sells spatial tissue-mapping instruments, kits, and services to the same academic and pharma customers AtlasXomics targets, albeit in transcriptomics rather than epigenomics.
- NanoString Technologies (a Bruker Company): Spatial biology platforms including GeoMx digital spatial profiling and CosMx SMI. Overlaps with AtlasXomics in spatial tissue characterization, multi-omic readouts, and academic/industry customer base, though focused on transcriptomics and proteomics today.
- Akoya Biosciences: Spatial proteomics and tissue imaging platforms (CODEX, Phenoptics). Targets the same translational research and pharma biomarker customers seeking spatial tissue context, providing a relevant competitive benchmark on instrument-plus-kit commercial models.
- Vizgen: MERFISH-based spatial transcriptomics platform with instruments and consumables. Comparable as a venture-stage spatial omics player selling integrated instrument-plus-kit solutions to academic and pharma customers, with overlapping grant-funded adoption drivers.
- Resolve Biosciences: Molecular Cartography spatial multi-omics platform offering high-plex spatial transcriptomics services and instruments. Directly comparable as a spatial omics company serving research institutions and pharma with tissue-context molecular readouts.
Emerging players
- Active Motif: Epigenomics products and services company offering chromatin immunoprecipitation kits, histone modification assays, and related services. Comparable as a specialized epigenomics vendor competing for the same chromatin research budget and offering kit-plus-service commercial models.
- Diagenode: Epigenomics-focused life sciences company providing kits, antibodies, and services for chromatin research and ChIP-seq. Comparable as a niche epigenomics specialist with a kit-plus-services model targeting academic and industry researchers in chromatin biology.
- Cantata Bio (formerly Dovetail Genomics): 3D genomics and chromatin interaction mapping products and services using proximity ligation approaches. Comparable in serving chromatin/3D genomics research customers with spatial and structural readouts of genome organization.
- Singular Genomics: Sequencing and spatial multi-omics platform developer (G4 sequencing, Spatial sequencing). Adjacent peer offering instrument-based multi-omic spatial capabilities and pursuing similar academic and pharma customers as AtlasXomics.
- Element Biosciences: Sequencing platform (AVITI) with a roadmap toward multi-omic and chromatin-aware applications. Comparable as a venture-stage life-sciences tools company targeting research customers with modular, lower-cost instrumentation, similar to AtlasXomics' standard-equipment positioning.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
AtlasXomics social profiles
Digital presenceAtlasXomics financial estimates
Financial estimateRevenue estimate
Valuation estimate
AtlasXomics leadership team
Management profileNumber of profiles
Profiles10 records
AtlasXomics funding detail
Funding detailFunding overview
Funding rounds2 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
AtlasXomics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about AtlasXomics
What does AtlasXomics do?
AtlasXomics commercializes the proprietary DBiT-seq platform for spatial epigenomics, using orthogonal microfluidic barcoding to map open chromatin and chromatin marks directly on intact tissue sections at high resolution (48,400 pixels at 10×10 µm) without tissue dissociation. The company delivers this capability through three offerings: the DBiT-seq technology platform itself, FlowGel reagent kits for in-situ labeling and library preparation, and contract spatial epigenomics services that produce multi-omic tissue maps for academic and industry clients.
Is AtlasXomics a public or private company?
AtlasXomics is a private company. It is classified as venture growth investor backed and is currently operating.
When was AtlasXomics founded?
AtlasXomics was founded in 2020. It employs 11 to 50 people.
Where is AtlasXomics based?
AtlasXomics is headquartered in New Haven, United States, in the North America region.
How does AtlasXomics make money?
Two revenue lines are on record. Spatial Epigenomics Services are the primary driver. The others are early-Access Kits.
Who are AtlasXomics's main competitors?
Direct peers on record are 10x Genomics, NanoString Technologies (a Bruker Company), Akoya Biosciences, Vizgen and Resolve Biosciences. Emerging players are Active Motif, Diagenode, Cantata Bio (formerly Dovetail Genomics), Singular Genomics and Element Biosciences.
Does AtlasXomics have an API?
No public API is recorded for AtlasXomics.
What industry is AtlasXomics in?
AtlasXomics's product category is Spatial Epigenomics Services and Tools. Its primary akta.pro industry code is HLAGANAF, Epigenomics & Chromatin Profiling Services, with a secondary code of HLAGANAI, Bioinformatics, Multi-Omics Data Analysis & Interpretation Services. Its NAICS code is 621511 and its SIC code is 8071.